BRIEF-Sino Biopharmaceutical Says Positive Results From Phase III Study Of Benmelstobart Injection

Reuters
27 Dec 2024
BRIEF-Sino Biopharmaceutical Says Positive Results From Phase III Study Of Benmelstobart Injection

Dec 27 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:

  • BENMELSTOBART INJECTION PRIMARY STUDY ENDPOINT PROGRESSION-FREE SURVIVAL MET

Further company coverage: 1177.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10